Moderna’s results came as demand for its Covid-19 vaccine steadied following a prolonged decline. Humana said it had paid out slightly less of its premium revenue on medical expenses in the latest quarter, alongside raising its earnings projection for 2026.
Health-Care Stocks Hold Steady as Investors Favor Cyclicals
Health-care companies were little changed despite strong earnings, as traders shifted back toward cyclical sectors after strong jobs data. Moderna reported a third-quarter profit and lifted its full-year revenue growth forecast, while Humana shares gained on a higher 2026 earnings projection.
When reusing this material a link to Money Talk is required.
Comments (0)
No comments yet. Be the first!